Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-baseGlobeNewsWire • 12/13/21
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)GlobeNewsWire • 11/04/21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021GlobeNewsWire • 10/19/21
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)GlobeNewsWire • 10/01/21
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical CancerBusiness Wire • 09/20/21
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical CancerBusiness Wire • 09/20/21
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021GlobeNewsWire • 09/19/21
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The LancetPRNewsWire • 09/09/21
Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/11/21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021GlobeNewsWire • 07/21/21
